<table>
<thead>
<tr>
<th>AGENDA ITEM</th>
<th>PURPOSE</th>
<th>PRESIDER/PRESENTER(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday, October 27, 2010</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>Welcome &amp; Introductions</td>
<td>Dr. Carol Baker (Chair, ACIP) Dr. Larry Pickering (Executive Secretary, ACIP; CDC)</td>
</tr>
<tr>
<td>8:30</td>
<td>Meningococcal Vaccine</td>
<td>Information Discussion Vote Dr. Cody Meissner (ACIP, WG Chair) Dr. Amanda Cohn (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>- Introduction</td>
<td>Information Discussion Vote Dr. Ismael Ortega-Sanchez (CDC/NCIRD) Dr. Allison Kempe (University of Colorado)</td>
</tr>
<tr>
<td></td>
<td>- Considerations for people at high risk for meningococcal disease to receive 2-dose 1° series</td>
<td>Information Discussion Vote Dr. Amanda Cohn (CDC/NCIRD) Dr. Lance Rodewald (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>- Cost-effectiveness of adolescent meningococcal vaccination</td>
<td>Information Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Provider attitudes &amp; practices regarding adolescent meningococcal vaccination</td>
<td>Information Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Considerations regarding adolescent meningococcal vaccination</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td>Break</td>
</tr>
<tr>
<td>10:30</td>
<td>Hepatitis B Vaccine</td>
<td>Information &amp; Discussion Vote Dr. Kathy Byrd (CDC/NCHHSTP) Dr. Mark Sawyer (ACIP, WG Chair) Dr. Joseph Perz (CDC/NCEZID) Dr. Trudy Murphy (CDC/NCHHSTP)</td>
</tr>
<tr>
<td></td>
<td>- HepB vaccine coverage in high risk adults</td>
<td>Information Discussion &amp; Dr. Trudy Murphy (CDC/NCHHSTP)</td>
</tr>
<tr>
<td></td>
<td>- Work Group introduction</td>
<td>&amp; Dr. Trudy Murphy (CDC/NCHHSTP)</td>
</tr>
<tr>
<td></td>
<td>- Infection control initiatives</td>
<td>Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Review of hepatitis B in adults with diabetes</td>
<td>Information Discussion Vote Dr. Amanda Cohn (CDC/NCIRD) Dr. Lance Rodewald (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>- Policy considerations - HepB vaccination for adults with diabetes</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td>Lunch</td>
</tr>
<tr>
<td>1:30</td>
<td>Pertussis Vaccines</td>
<td>Information &amp; Discussion Vote Dr. Mark Sawyer (ACIP, WG Chair) Dr. Kathleen Harriman (CA Dept of Public Health) Dr. Jennifer Liang (CDC/NCIRD) Dr. Lance Rodewald (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>- Update on Pertussis Vaccines Work Group activities</td>
<td>Information &amp; Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Update on pertussis outbreak - California, 2010</td>
<td>Information &amp; Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Proposed recommendation for use of Tdap regardless of Td interval</td>
<td>Information &amp; Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Safety and immunogenicity of Tdap in people ≥65 years of age</td>
<td>Information &amp; Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Proposed recommendation for use of Tdap in people ≥65 years of age</td>
<td>Information &amp; Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Proposed recommendation for use of Tdap in undervaccinated children 7-10 years of age</td>
<td>Information &amp; Discussion Vote</td>
</tr>
<tr>
<td>3:45</td>
<td></td>
<td>Break</td>
</tr>
<tr>
<td>4:00</td>
<td>Evidence Based Recommendations</td>
<td>Information &amp; Discussion Vote Dr. Jon Temte (ACIP, WG Chair) Dr. Faruque Ahmed (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>- Introduction</td>
<td>Information &amp; Discussion Vote</td>
</tr>
<tr>
<td></td>
<td>- Evidence-based format for ACIP recommendations: based on GRADE (Grades of Recommendation Assessment, Development, and Evaluation)</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>Public Comment</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Thursday, October 28, 2010

8:00 Unfinished Business
  ▪ Update: Herpes Zoster (Shingles) Work Group
  Information
  Dr. Carol Baker (Chair, ACIP)
  Dr. Paul Cieslak (ACIP, WG Chair)
8:15 Agency Updates (CDC, CMS, DOD, DVA, FDA, HRSA, IHS, NIH, NVAC, NVPO)
  Information
  ACIP Ex Officio Members
8:30 Human Papillomavirus (HPV) Vaccines
  ▪ Introduction
  ▪ HPV vaccine safety - Vaccine Safety Datalink
  Information
  Dr. Janet Englund (ACIP Member)
  Ms. Julianne Gee (CDC/NCEZID)
  Ms. Shannon Stokley (CDC/NCIRD)
  Dr. Richard Haupt (Merck)
  Dr. Mandy Allison (University of Colorado)
  Dr. Harrell Chessen (CDC/NCHHSTP)
  Dr. Lauri Markowitz (CDC/NCHHSTP)
  ▪ HPV vaccine uptake in females and program issues
  ▪ HPV4 in males: clinical trial data
  Information
  &
  Dr. Lance Rodewald (CDC/NCIRD)
  ▪ Provider attitudes and practices regarding HPV vaccine use in males
  ▪ Review of cost effectiveness of male HPV vaccination
  ▪ Considerations for HPV vaccination recommendations in males
  Discussion
  Ms. Kris Ehresmann (ACIP, WG Chair)
  Dr. Abigail Shefer (CDC/NCIRD)
10:20 Vaccine Supply
  Information
  Dr. Lance Rodewald (CDC/NCIRD)
10:30 Break
11:00 2011 Immunization Schedule - 0-18 years of age
  Information
  Dr. Cody Meissner (ACIP, WG Chair)
  Dr. William Atkinson (CDC/NCIRD)
11:30 2011 Immunization Schedule - 19 years of age and older
  Information
  Dr. Abigail Shefer (CDC/NCIRD)
12:00 Lunch
1:00 Rotavirus Vaccines
  ▪ Introduction
  ▪ Intussusception following administration of rotavirus vaccine (RV): GSK study, Mexico
  Information
  Dr. Lance Chilton (ACIP, WG Chair)
  Dr. Romulo Colindres, Director, GSK Biologicals
  Dr. Manish Patel (CDC/NCIRD)
  &
  Dr. James Baggs (CDC/NCEZID)
  ▪ Intussusception following administration of RV: PAHO study, Brazil and Mexico
  ▪ US data on intussusception following administration of rotavirus vaccine (RV)
  ▪ Update: intussusception data; porcine circovirus
  Discussion
  Dr. Christopher Mast, Dr. Colette Ranucci (Merck)
  Dr. Julie Bines (University of Melbourne, Australia)
  Dr. Margaret Cortese (CDC/NCIRD)
3:00 Influenza
  ▪ Introduction
  ▪ Influenza activity worldwide
  Information
  Dr. Wendy Keitel (ACIP, WG Chair)
  &
  Dr. Tim Uyeki (CDC/NCIRD)
  ▪ Influenza vaccine availability
  ▪ Influenza vaccine safety
  Discussion
  Dr. Lance Rodewald (CDC/NCIRD)
  Dr. Tom Shimabukuro (CDC/NCEZID)
3:30 Public Comment
3:45 Adjourn

Acronyms
- CMS Centers for Medicare and Medicaid Services
- NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention
- DOD Department of Defense
- NCIRD National Center for Immunization & Respiratory Diseases
- DVA Department of Veterans Affairs
- NIH National Institutes of Health
- FDA Food and Drug Administration
- NVAC National Vaccine Advisory Committee
- HRSA Health Resources and Services Administration
- NVPO National Vaccine Program Office
- IHS Indian Health Service
- WG Work Group
- NCEZID National Center for Emerging and Zoonotic Infectious Diseases

This document can be found on the CDC website at: http://www.cdc.gov/vaccines/recs/acip/downloads/agenda-oct10.pdf